Cell>Point Announces Encouraging Results From 99mTc-EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease
4/10/2013 12:09:29 PM
More...
|
Cell>Point and HYUN IMC Expand License in South Korea to Include Hanmi Pharmaceutical, Co., Ltd for Cancer and Heart Disease Imaging
3/12/2013 9:35:26 AM
More...
|
Cell>Point to Present at the 26th Indian Cooperative Oncology Network (ICON) Meeting in Bengaluru, India
3/20/2012 6:11:43 AM
More...
|
Cell>Point Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Technetium-99m-EC-G for Imaging Lung Cancer
3/13/2012 10:38:06 AM
More...
|
Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent, Technetium-99m EC-G
2/29/2012 6:53:34 AM
More...
|
Cell>Point Executes Brazil License with Radiopharmacus for Cancer and Heart Disease Molecular Imaging Drug, EC-G
1/25/2012 6:50:02 AM
More...
|
Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G SPECT Cancer Imaging Agent to FDG PET at Society of Nuclear Medicine Annual Meeting June 7, 2011
6/6/2011 10:34:08 AM
More...
|
Cell>Point Completes Phase 2 of Cancer Diagnostic Phase 2/3 Trial
6/29/2010 8:17:08 AM
More...
|
Cell>Point Completes Phase 2 of Cancer Diagnostic Phase 2/3 Trial
6/28/2010 1:58:28 PM
More...
|
Cell>Point Submits Investigational New Drug Application for Phase 1b/2 Trial of 99mTc-EC-G in Assessing Coronary Artery Disease
6/22/2010 11:49:16 AM
More...
|
|